Audit 357536

FY End
2024-12-31
Total Expended
$48.55M
Findings
0
Programs
67
Year: 2024 Accepted: 2025-05-29
Auditor: Moss Adams LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.855 Allergy and Infectious Diseases Research $24.00M Yes 0
93.855 Consortium for Hiv/aids Vaccine Development $3.50M Yes 0
93.U03 75n93019c00001 Iedb-06 $3.15M Yes 0
93.396 Cancer Biology Research $1.91M Yes 0
93.384 Advanced Research Projects Agency for Health (arpa-H) $1.63M Yes 0
93.859 Biomedical Research and Research Training $1.32M Yes 0
93.U08 75n93019c00067- Tb $1.01M Yes 0
93.394 Cancer Detection and Diagnosis Research $887,475 Yes 0
93.855 Airway Inflammation and Airway Remodeling in Severe Asthma $752,602 Yes 0
93.855 Transcription Factor Regulation of Cd4 and Cd8 T Cell Effector and Memory Differentiation and Function $735,817 Yes 0
93.U07 75n93019c00066- Bordetella $731,624 Yes 0
93.U06 75n93019c00065- Zika/chikv $675,198 Yes 0
93.395 Cancer Treatment Research $608,628 Yes 0
93.855 The Development and Evaluation of Pan-Coronavirus Vaccines $512,874 Yes 0
93.353 Personalized Neuroblastoma Vaccines $452,869 Yes 0
93.855 Discovering Durable Pan-Coronavirus Immunity $436,616 Yes 0
93.U13 Collaborative Influenza Vaccine Innovation Centers (civics) Component A: Vaccine Center $404,127 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $387,369 Yes 0
93.310 Trans-Nih Research Support $334,192 Yes 0
93.855 Protective Immunity Following Dengue Virus Natural Infections and Vaccination $333,812 Yes 0
93.393 Cancer Cause and Prevention Research $321,461 Yes 0
93.855 I-Akc: Integrated Airr Knowledge Commons $299,133 Yes 0
93.855 Flavivirus and Alphavirus Revampp (flare) $285,697 Yes 0
93.855 B and T Cell Biology of Protection From and Eradication of Siv/shiv Infection $277,559 Yes 0
93.U10 75n93024c00057- Pneumonia $274,734 Yes 0
93.839 Neutrophil Lineage in Inflammation $202,844 Yes 0
93.U05 75n93019c00065- Chim Zika $199,419 Yes 0
93.U14 Development of An Ebolavirus Sudan Vaccine Utilizing A Live Vesicular Stomatitis Virus Chimera Platform $182,449 Yes 0
93.395 Irreversible Electroporation (ire) Combined with Cd40 Agonism As in Situ Vaccine Therapy for Pancreatic Cancer $178,887 Yes 0
93.855 Semantic Integration of Protein Epitopes and Functional Features for Infectious and Autoimmune Disease Knowledge Discovery $177,514 Yes 0
93.866 Inflammatory Mediators of Sex Differences in Alzheimer's Disease, A Humans to Mouse Approach $151,945 Yes 0
93.855 Thermostable Measles Fusion Glycoprotein As A New Vaccine Strategy $135,381 Yes 0
93.855 Childhood Asthma in Urban Settings Clinical Research Network (cause) – Leadership Center $134,552 Yes 0
93.350 National Center for Advancing Translational Sciences $124,317 Yes 0
93.855 Development of Neutralizing Antibodies to MacHupo Virus $118,678 Yes 0
93.242 Dysregulation of Trio Gef1 Activity in Nuerodevelopmental Disorders $117,740 Yes 0
93.U01 75n93019c00001- Cd3 $111,000 Yes 0
93.837 Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk $108,667 Yes 0
93.U04 75n93019c00001 Iedb-07 $103,197 Yes 0
93.855 Fusion Peptide Directed Immunogens That Elicit Neutralizing and Protective Antibodies in Non-Human Primates $102,151 Yes 0
93.855 Emerging Infections: Surveillance, Epidemiology and Pathogenesis $92,948 Yes 0
93.310 Epigenetic Regulation of Epidermal Proinflammatory Responses $91,711 Yes 0
93.855 Design and Testing of Germline-Targeting and Boosting Immunogens to Elicit 10e8-Like Broadly Neutralizing Antibodies Against Hiv $90,686 Yes 0
93.855 Immune Engineering of Optimized Sequential Immunization Strategies for Hiv Vaccines $81,669 Yes 0
93.855 Genetics Linkage in Lupus $80,628 Yes 0
93.394 Sars-Cov-2 Correlates of Protection in A Latin-Orgin Population $75,952 Yes 0
93.395 Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer $73,265 Yes 0
47.074 Mechanisms of A Natural Bacterial Biosensor Using Rt-Dna $65,210 Yes 0
93.384 Protect Against Emergent Alphaviruses Through Computation $60,864 Yes 0
93.395 Harnessing Cmv-Specific T Cells for Tumor Immunotherapy $55,351 Yes 0
93.U12 The Breadth of Cross-Reactivity of T Cell Responses Elicited by Different Vaccination Regimensmeasured Against Different Sarbeco and Merbeco Viral Sequences $51,924 Yes 0
93.847 Tweak/tnfsf12 and Light/tnfsf14 Interactions in Allergic Esophagitis Remodeling $45,235 Yes 0
93.397 Specialized Cancer Center Core Support Grant $40,173 Yes 0
93.395 Evaluation of T Follicular Regulatory Cells As Novel Cellular Targets of Cancer Immunotherapy $39,996 Yes 0
93.855 Ige Antibody Responses to the Oligosaccharide Galactose-Alpha-1,3-Galactose (alphagal) in Murine and Human Atherosclerosis $39,706 Yes 0
93.855 Targeting of Somatic Hypermutation in the Genome $32,946 Yes 0
93.U09 75n93024c00056- Pp $29,704 Yes 0
93.855 Mechanism and Regulation of V(d)j Recombination $23,154 Yes 0
93.395 Optimizing Immunoradiotherapy for Hnscc $21,895 Yes 0
93.847 San Diego Digestive Diseases Research Center $21,391 Yes 0
93.855 Identifying Individuals at Risk of Progression to Activate Tuberculosis $18,266 Yes 0
93.310 Spatial Mapping Senescent Cells Across the Mouse Lifespan by Multiplex Transcriptions and Epignenomics $18,117 Yes 0
93.U15 Cryoelectron Microscopy Support $16,970 Yes 0
93.855 Impact of Sars-Cov-2 Infection on Reactivation of Latent Mtb Infections in A Prospective Kenyan Cohort $9,510 Yes 0
93.U11 Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (impac-Tb) $8,122 Yes 0
93.837 Immunologic, Inflammatory, and Clinical Contributors to Hiv-Related Heart Failure with Preserved Ejection Fraction (hepef) $3,233 Yes 0
93.U02 75n93019c00001 Iedb -05 $-5,475 Yes 0

Contacts

Name Title Type
ZPAUY3FQMM26 Victoria Kern Auditee
8587526557 Scott Simpson Auditor
No contacts on file

Notes to SEFA

Title: Note 1 – Basis of Presentation Accounting Policies: Note 2 – Summary of Significant Accounting Policies Expenditures reported on the Institute are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowed or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. De Minimis Rate Used: N Rate Explanation: Note 3 – Indirect Cost Rate The Institute has elected not to use the 10 percent de minimus indirect cost rate as allowed under Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of La Jolla Institute for Immunology (the Institute) under programs of the federal government for the year ended December 31, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because it presents only a selected portion of the operations of the Institute, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of the Institute.